Blau Farmacêutica Balance Sheet Health
Financial Health criteria checks 6/6
Blau Farmacêutica has a total shareholder equity of R$2.0B and total debt of R$570.2M, which brings its debt-to-equity ratio to 28.6%. Its total assets and total liabilities are R$3.1B and R$1.1B respectively. Blau Farmacêutica's EBIT is R$329.3M making its interest coverage ratio -13.9. It has cash and short-term investments of R$407.3M.
Key information
28.6%
Debt to equity ratio
R$570.22m
Debt
| Interest coverage ratio | -13.9x |
| Cash | R$407.31m |
| Equity | R$2.00b |
| Total liabilities | R$1.06b |
| Total assets | R$3.05b |
Recent financial health updates
No updates
Recent updates
Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop
Feb 01
What Does The Future Hold For Blau Farmac êutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates
May 14Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next
Feb 24Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely
Oct 14Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)
Aug 17Financial Position Analysis
Short Term Liabilities: BLAU3's short term assets (R$1.6B) exceed its short term liabilities (R$335.9M).
Long Term Liabilities: BLAU3's short term assets (R$1.6B) exceed its long term liabilities (R$722.4M).
Debt to Equity History and Analysis
Debt Level: BLAU3's net debt to equity ratio (8.2%) is considered satisfactory.
Reducing Debt: BLAU3's debt to equity ratio has reduced from 100.8% to 28.6% over the past 5 years.
Debt Coverage: BLAU3's debt is well covered by operating cash flow (38.7%).
Interest Coverage: BLAU3 earns more interest than it pays, so coverage of interest payments is not a concern.